Ion channel inhibitor - Boehringer Ingelheim
Latest Information Update: 07 Jun 2024
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Respiratory tract disorders
Most Recent Events
- 29 Feb 2024 Phase-I clinical trials in Respiratory tract disorders (unspecified route) prior to April 2024 (Boehringer Ingelheim Pipeline, February 2024)